IL17A Inhibitor in RA

Targeting interleukin-17 in patients with active rheumatoid arthritis: rationale and clinical potential

Image result for il23 rheumatoid

Clinical and experimental evidence suggest that interleukin-17A (IL-17A; also known as IL-17) is an attractive therapeutic target in rheumatoid arthritis (RA). Rheumatoid synovial tissue produces IL-17A, which causes cartilage and bone degradation in …
ncbi.nlm.nih.gov

IL-17A Blocker Disappoints in RA

Secukinumab fails to match abatacept in head-to-head trial
medpagetoday.com

ACR: Anti-IL17 Drug Misses Endpoint in RA Trial

ATLANTA — An investigational biologic drug with a…
medpagetoday.com